Optimal Duration News Today

Steering an organization through challenging times intersects business leadership, geopolitics, and the Board’s duty of care.

An aspirin-free strategy following percutaneous coronary intervention was found to not be superior for 1-month outcomes.

Clopidogrel after PCI was noninferior to aspirin for net adverse clinical events but superior in reducing secondary endpoints of stroke and MI, in 5-year STOPDAPT-2 results.

The WHO has decided to not add GLP-1 receptor agonists indicated for weight loss to its 2023 essential medicines list. Data are lacking on long term efficacy, the WHO said.

Clopidogrel monotherapy after 1 month of DAPT following PCI decreases risk for major bleeding regardless of if a patient has diabetes.

Clinical studies presented at the American Heart Association 2022 Scientific Sessions event demonstrate compelling diagnostic and health economic value of the Zio suite of products across a range of clinical applications 

Запомнить мои ответы для этой формы на этом компьютере {"commentics_url":"\/\/express-novosti.ru\/comments\/","page_id":960877,"enabled_country":false,"enabled_state":false,"state_id":0,"enabled_upload":false,"maximum_upload_amount":3,"maximum_upload_size":5,"maximum_upload_total":5,"securimage":true,"securimage_url":"\/\/express-novosti.ru\/comments\/3rdparty\/securimage\/securimage_show.php?namespace=cmtx_960877","lang_error_file_num":"\u041c\u043...

SCAI 2021 Late-breaking Clinical Study Results SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI. April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the Society for Cardiovascular Angiograph...